Looking for Golimumab found 17 matches
|
| Open monograph to display formulary status |
BNF Category |
| |
Golimumab
|
Gastro-intestinal system - Tumor necrosis factor alpha (TNF-a) inhibitors - 01.05.03
|
| |
Golimumab
|
Gastro-intestinal system - Tumor necrosis factor alpha (TNF-a) inhibitors - 01.05.03
|
| |
Golimumab
(Simponi®)
|
Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
|
| |
Links Link to Drug Section  Link to document |
|
LSCMMG: Golimumab (01.05.03)
|
|
NICE TA220: Golimumab for the treatment of psoriatic arthritis (10.01.03)
|
|
NICE TA225: Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs (10.01.03)
|
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
|
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
|
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis (10.01.03)
|
|
|
